Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMDW) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for Revolution Medicines (RVMDW) over the last 8 years, with Q3 2025 value amounting to $2.3 billion.

  • Revolution Medicines' Liabilities and Shareholders Equity rose 2773.23% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 billion, marking a year-over-year increase of 2736.38%. This contributed to the annual value of $2.6 billion for FY2024, which is 2408.67% up from last year.
  • Revolution Medicines' Liabilities and Shareholders Equity amounted to $2.3 billion in Q3 2025, which was up 2773.23% from $2.4 billion recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Liabilities and Shareholders Equity registered a high of $2.6 billion during Q4 2024, and its lowest value of $632.8 million during Q2 2022.
  • In the last 5 years, Revolution Medicines' Liabilities and Shareholders Equity had a median value of $1.1 billion in 2023 and averaged $1.4 billion.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 1824.75% in 2022, then soared by 15392.64% in 2023.
  • Quarter analysis of 5 years shows Revolution Medicines' Liabilities and Shareholders Equity stood at $738.0 million in 2021, then increased by 10.02% to $811.9 million in 2022, then skyrocketed by 153.93% to $2.1 billion in 2023, then increased by 24.09% to $2.6 billion in 2024, then dropped by 11.98% to $2.3 billion in 2025.
  • Its last three reported values are $2.3 billion in Q3 2025, $2.4 billion for Q2 2025, and $2.4 billion during Q1 2025.